Core Viewpoint - China SXT Pharmaceuticals, Inc. has regained compliance with Nasdaq's Minimum Bid Price Requirement after a share consolidation, closing the matter with Nasdaq [1][4]. Group 1: Compliance Notification - The Company received a Compliance Notice from Nasdaq on March 13, 2025, confirming compliance with the Minimum Bid Price Requirement [1]. - Previously, on October 3, 2024, the Company was notified of its failure to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days [2]. - The Company was given until April 1, 2025, to regain compliance under Nasdaq Listing Rules [2]. Group 2: Share Consolidation - To meet the Minimum Bid Price Requirement, the Company executed a share consolidation on February 25, 2025, consolidating every eight ordinary shares into one [3]. - Following the consolidation, the Company achieved a closing bid price of at least US$1.00 per share for 10 consecutive business days from February 25, 2025, to March 12, 2025 [4]. Group 3: Company Overview - China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China [5]. - The Company specializes in the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (TCMPs) and TCM Homologous Supplements (TCMHS) [5].
China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency